| Kelly Heilman, APRN | |
|
131 New London Tpke Ste 101, Glastonbury, CT 06033-2246 | |
| (860) 659-8904 | |
| (860) 246-5828 |
| Full Name | Kelly Heilman |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 131 New London Tpke Ste 101, Glastonbury, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316497662 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allergy Associates Of Hartford, Pc | 0648173500 | 4 |
News Archive
New research published in the December issue of the Journal of the American College of Surgeons (JACS) suggests that surgical procedures that are shorter in duration and the use of fewer blood transfusions characterize hospitals that have a lower incidence of surgical site infections (SSI).
DAMAGING a cell's nucleolus could destroy cancer cells by increasing levels of the most important tumour prevention protein, p53, reveals research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, today.
In 2009, Mitch Stone was 11 when he was diagnosed with a brain tumor. He went through very aggressive treatments at Cincinnati Children's.
Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).
› Verified 8 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770696643 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000752 |
News Archive
New research published in the December issue of the Journal of the American College of Surgeons (JACS) suggests that surgical procedures that are shorter in duration and the use of fewer blood transfusions characterize hospitals that have a lower incidence of surgical site infections (SSI).
DAMAGING a cell's nucleolus could destroy cancer cells by increasing levels of the most important tumour prevention protein, p53, reveals research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, today.
In 2009, Mitch Stone was 11 when he was diagnosed with a brain tumor. He went through very aggressive treatments at Cincinnati Children's.
Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).
› Verified 8 days ago
| Entity Name | Allergy Associates Of Hartford, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003937988 PECOS PAC ID: 0648173500 Enrollment ID: O20040128000984 |
News Archive
New research published in the December issue of the Journal of the American College of Surgeons (JACS) suggests that surgical procedures that are shorter in duration and the use of fewer blood transfusions characterize hospitals that have a lower incidence of surgical site infections (SSI).
DAMAGING a cell's nucleolus could destroy cancer cells by increasing levels of the most important tumour prevention protein, p53, reveals research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, today.
In 2009, Mitch Stone was 11 when he was diagnosed with a brain tumor. He went through very aggressive treatments at Cincinnati Children's.
Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).
› Verified 8 days ago
| Entity Name | Hartford Healthcare Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043561301 PECOS PAC ID: 1153573902 Enrollment ID: O20121201000007 |
News Archive
New research published in the December issue of the Journal of the American College of Surgeons (JACS) suggests that surgical procedures that are shorter in duration and the use of fewer blood transfusions characterize hospitals that have a lower incidence of surgical site infections (SSI).
DAMAGING a cell's nucleolus could destroy cancer cells by increasing levels of the most important tumour prevention protein, p53, reveals research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, today.
In 2009, Mitch Stone was 11 when he was diagnosed with a brain tumor. He went through very aggressive treatments at Cincinnati Children's.
Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Heilman, APRN 131 New London Tpke Ste 101, Glastonbury, CT 06033-2246 Ph: (860) 659-8904 | Kelly Heilman, APRN 131 New London Tpke Ste 101, Glastonbury, CT 06033-2246 Ph: (860) 659-8904 |
News Archive
New research published in the December issue of the Journal of the American College of Surgeons (JACS) suggests that surgical procedures that are shorter in duration and the use of fewer blood transfusions characterize hospitals that have a lower incidence of surgical site infections (SSI).
DAMAGING a cell's nucleolus could destroy cancer cells by increasing levels of the most important tumour prevention protein, p53, reveals research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, today.
In 2009, Mitch Stone was 11 when he was diagnosed with a brain tumor. He went through very aggressive treatments at Cincinnati Children's.
Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).
› Verified 8 days ago